Any current/future new fundraising through debt or equity?

During Q2 FY23, Balaxi Pharmaceuticals completed issuance of equity shares and warrants aggregating to INR 49.61 crore on a preferential basis. The proceeds from this equity fundraising are planned to partly finance the new EU-GMP-compliant manufacturing facility. No specific mention of new or future debt fundraising was made in the transcript. Bank limits and potential cost overruns related to the new plant were questioned, but no detailed disclosure on new debt or additional equity beyond the mentioned preferential issue was provided.

Any current/future capex/capital investment/strategic investment?

Balaxi Pharmaceuticals is setting up an EU-GMP compliant pharmaceutical manufacturing unit near Hyderabad. Groundbreaking for the plant is scheduled for December 12, 2022. The commissioning of the unit is targeted for March 2024. This plant is a backward integration project aimed at reducing product costs. Post commissioning, the plant is expected to gain EU-GMP approval within about six months, enabling entry into new markets in Southeast Asia, Central Africa, and Latin America. The new facility will support manufacturing of Oral Solid Dosages and Liquid Injectables. Capital raised includes I

Future growth expectations in sales/revenue/volumes?

Revenues for Q2 stood at INR 86.40 crore, with 23% quarter-on-quarter growth, driven by strong volume growth in Latin America. Strong expansion expected in established markets like the Dominican Republic and Guatemala. Nascent markets such as Honduras and El Salvador are anticipated to scale up revenues in coming quarters. Over 745 product registrations currently active in six countries; 646 new registrations submitted or in pipeline. Launch of new products planned leading to further improvements in all covered countries. EU-GMP compliant manufacturing unit commissioning targeted for March 202

Future growth expectations in earnings/operating earnings/profits/EPS?

FY24-25: Expected increase in profitability and volumes due to commissioning of EU-GMP compliant plant. New plant will enable backward integration, reducing product costs and improving delivery control. EU-GMP approval anticipated ~6 months post-commissioning will open new markets in Southeast Asia, Central Africa, and Latin America. Quality advantage of EU-GMP compliance expected to command 3%-4% better pricing. Direct revenue benefits from new plant expected to start from FY25-26. Q2 FY23 PAT rose 28.5% YoY to INR 15.50 crore; EPS for the quarter at INR 15.49. Sustained growth driven by stro

IN US

Sale is live|00:00:00left today

Balaxi Pharmaceuticals LtdQ3 FY22Pharmaceuticals & Biotechnology

Balaxi Pharmaceuticals Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹23.1P/E: 15.6Market Cap: ₹147 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Revenues for Q2 stood at INR 86.40 crore, with 23% quarter-on-quarter growth, driven by strong volume growth in Latin America.
→Strong expansion expected in established markets like the Dominican Republic and Guatemala.
→Nascent markets such as Honduras and El Salvador are anticipated to scale up revenues in coming quarters.
→Over 745 product registrations currently active in six countries; 646 new registrations submitted or in pipeline.
→Launch of new products planned leading to further improvements in all covered countries.
→EU-GMP compliant manufacturing unit commissioning targeted for March 2024 will boost backward integration and open new markets in Southeast Asia, Central Africa, and Latin America.
→Expected profitability and volumes to increase from FY24-25, with direct revenue benefits from the plant starting FY25-26.
→Anticipated price advantage of 3%-4% due to improved quality and regulatory certifications.

Margin guidance

Category 3

→FY24-25: Expected increase in profitability and volumes due to commissioning of EU-GMP compliant plant.
→New plant will enable backward integration, reducing product costs and improving delivery control.
→EU-GMP approval anticipated ~6 months post-commissioning will open new markets in Southeast Asia, Central Africa, and Latin America.
→Quality advantage of EU-GMP compliance expected to command 3%-4% better pricing.
→Direct revenue benefits from new plant expected to start from FY25-26.
→Q2 FY23 PAT rose 28.5% YoY to INR 15.50 crore; EPS for the quarter at INR 15.49.
→Sustained growth driven by strong volume growth in Latin American markets and ongoing product launches.
→EBITDA margin improved to 17.1%, reflecting scaling in newer geographies and cost absorption.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→During Q2 FY23, Balaxi Pharmaceuticals completed issuance of equity shares and warrants aggregating to INR 49.61 crore on a preferential basis.
→The proceeds from this equity fundraising are planned to partly finance the new EU-GMP-compliant manufacturing facility.
→No specific mention of new or future debt fundraising was made in the transcript.
→Bank limits and potential cost overruns related to the new plant were questioned, but no detailed disclosure on new debt or additional equity beyond the mentioned preferential issue was provided.

Order book

Yes

The transcript does not specifically mention the current or expected order book or pending orders in exact numbers. However, relevant information includes: - Balaxi Pharmaceuticals currently has 745 product registrations in six countries. - There are 646 new registrations submitted or in the pipeline to be submitted to various health departments in different countries. - The company is expecting significant scale-up in revenues from nascent markets like Honduras and El Salvador in coming quarters. - The new EU-GMP compliant manufacturing plant will enable expansion into new markets (Southeast Asia, Central Africa, Latin America) after approval, potentially increasing order flow and revenues from FY24-25 onwards. No explicit orderbook or pending order values are disclosed in the available transcript.

Capex plans

Yes

→Balaxi Pharmaceuticals is setting up an EU-GMP compliant pharmaceutical manufacturing unit near Hyderabad.
→Groundbreaking for the plant is scheduled for December 12, 2022.
→The commissioning of the unit is targeted for March 2024.
→This plant is a backward integration project aimed at reducing product costs.
→Post commissioning, the plant is expected to gain EU-GMP approval within about six months, enabling entry into new markets in Southeast Asia, Central Africa, and Latin America.
→The new facility will support manufacturing of Oral Solid Dosages and Liquid Injectables.
→Capital raised includes INR 49.61 crore through equity and warrants on a preferential basis to partly finance the EU-GMP compliant facility.
→Construction tenders and detailed designing are underway as of November 2022.
→The investment is expected to improve profitability, volume, and market presence starting FY24-25 and yield revenue benefits from FY25-26 onwards.

How does Balaxi Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Balaxi Pharmaceuticals Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Balaxi Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio